Hence, in CKD models, systemic activation of ActRllA and Act-A levels exerted a positive SMAD-mediated regulatory effect on receptor activator of nuclear factor kappa-B ligand (RANKL), leading to osteoclastogenesis. Here, ACTA1 is linked to chronic kidney disease.